Key terms
About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest JNJ news
Yesterday
5:19am ET
Johnson & Johnson’s Strategic Settlement Plan for Ovarian Cancer Talc Claims: Financial Implications and Outlook
Yesterday
5:16am ET
Hold Rating on Johnson & Johnson Amid Ongoing Talc Litigation Uncertainties and Settlement Efforts
May 01
12:15pm ET
Johnson & Johnson (NYSE:JNJ) Is Paying $6.5B to Settle Lawsuit
May 01
11:45am ET
Johnson & Johnson management to meet with Oppenheimer
May 01
7:12am ET
Johnson & Johnson Announces Major Talc Litigation Settlement Plan
May 01
6:37am ET
J&J says talc plan commits company to pay claimants $6.475B
May 01
6:35am ET
J&J’s LLT proposes to resolve all ovarian cancer talc claims via reorganization
May 01
6:32am ET
J&J’s LLT proposes to resolve all ovarian cancer talc claims via reorganization
May 01
4:55am ET
Johnson & Johnson management to meet with Oppenheimer
Apr 30
10:13am ET
FTC expands patent listing challenges for drugs
Apr 29
10:20am ET
J&J receives positive CHMP opinion recommending approval of Sirturo in MDR TB
Apr 24
11:24pm ET
LLY vs. JNJ: Which Big Pharma Stock Is Better?
Apr 24
4:13pm ET
Cidara Therapeutics reacquires rights to CD388 from Johnson & Johnson for $85M
Apr 24
2:23pm ET
Johnson & Johnson management to meet with Oppenheimer
Apr 22
1:08pm ET
Legend Biotech says Carvykti approved by EC for second-line multiple myeloma
Apr 22
7:56am ET
Stryker added to ‘Tactical Outperform’ list at Evercore ISI
Apr 19
3:36pm ET
Johnson & Johnson (NYSE:JNJ) Notches Up After Talc Win
Apr 18
9:43am ET
Johnson & Johnson upgraded to Buy at HSBC with shares at three year lows
Apr 18
9:13am ET
Johnson & Johnson upgraded to Buy from Hold at HSBC
Apr 18
1:56am ET
Hold Rating on Johnson & Johnson Amidst Growth, Competition, and Legal Challenges
Apr 18
12:30am ET
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Johnson & Johnson (JNJ) and Lantheus (LNTH)
Apr 17
8:52am ET
Johnson & Johnson price target lowered to $175 from $181 at RBC Capital
Apr 17
6:19am ET
Johnson & Johnson price target lowered to $170 from $180 at BofA
Apr 17
5:20am ET
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Intra-Cellular Therapies (ITCI)
Apr 17
3:59am ET
RBC Capital Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)
Apr 16
1:35pm ET
Steady Performance and Aligned Guidance Justify Hold Rating for Johnson & Johnson
Apr 16
1:30pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cullinan Management (CGEM), Johnson & Johnson (JNJ) and UnitedHealth (UNH)
Apr 16
11:49am ET
J&J report ‘not alarming’ for Legend Biotech, says H.C. Wainwright
Apr 16
9:30am ET
Johnson & Johnson says no change to M&A strategy
Apr 16
8:58am ET
Johnson & Johnson says ‘off to solid financial start’ in 2024
Apr 16
8:15am ET
Balancing Act: Hold Rating on Johnson & Johnson Amid Steady Growth and Legal Challenges
No recent press releases are available for JNJ
JNJ Financials
Key terms
Ad Feedback
JNJ Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
JNJ Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range